What's Happening?
CroíValve, a medical device company, has announced the expansion of its Series B financing with an additional $27 million to support the DUO Adapt System in an enlarged TANDEM II study. This funding includes $20 million from Series B expansion and $7
million from European Innovation Council (EIC) and DTIF grants, bringing the total to $43 million. The DUO Adapt System is a novel transcatheter heart valve designed to treat tricuspid regurgitation (TR), a condition affecting over 4 million people in Europe and the U.S. The system works alongside the native tricuspid valve to restore function without invasive surgery. The expanded study will evaluate the system's safety and performance across multiple sites in the U.S. and EU, beyond the initial 15 patients treated.
Why It's Important?
The expansion of the DUO Adapt study is significant as it addresses a critical need in treating tricuspid regurgitation, a prevalent heart condition with limited non-surgical treatment options. The funding will enable CroíValve to accelerate clinical trials, potentially offering a less invasive solution for patients who are not candidates for surgery. This development could lead to improved quality of life for millions affected by TR and positions CroíValve as a key player in the structural heart device market. The involvement of major investors like BGF and EIC underscores the potential impact and market opportunity of this innovative technology.
What's Next?
With the additional funding, CroíValve plans to expand the TANDEM II study to include more sites and patients in the U.S. and EU. This will provide comprehensive data on the DUO Adapt System's effectiveness and safety, potentially leading to regulatory approvals and commercialization. The company aims to demonstrate the system's ability to treat large leaks and adapt to individual patient needs, which could revolutionize TR treatment. Stakeholders, including healthcare providers and patients, will be closely monitoring the study's outcomes, which could influence future treatment protocols and healthcare policies.
